Background. The OraQuick Advance Rapid HIV-1/2 Test is a point-of-care test capable of detecting human immunodeficiency virus (HIV)-specific antibodies in blood and oral fluid. To understand test performance and factors contributing to false-negative results in longitudinal studies, we examined results of participants enrolled in the Botswana TDF/FTC Oral HIV Prophylaxis Trial, the Bangkok Tenofovir Study, and the Bangkok MSM Cohort Study, 3 separate clinical studies of high-risk, HIV-negative persons conducted in Botswana and Thailand.
The recognition that immunoglobulin G (IgG) is present in oral fluid at levels sufficient to allow serological diagnosis of human immunodeficiency virus (HIV) infection has led to the development of rapid HIV tests based on oral fluid [1] . In June 2004, the OraQuick Rapid HIV-1/2 Antibody Test was approved by the US Food and Drug Administration (FDA) for use in oral fluid (OFOQ), and in July 2012 the test became the first overthe-counter rapid HIV test approved by the FDA for home use. The availability of a noninvasive, rapid HIV test that can be performed by nonprofessionals has greatly increased the accessibility of HIV testing. Among men who have sex with men (MSM), home test kits are acceptable, lead to increased testing, and reduce high-risk sexual encounters [2, 3] .
Rapid HIV tests may not perform as well as laboratory-based tests, and the advantages of oral fluid-based rapid testing must be weighed against possibly lower test accuracy. While the package inserts for OraQuick Advance and OraQuick HIV-1/2 (for use outside the United States) cite sensitivities of 99.3% and 100% and specificities of 99.8% and 99.9%, respectively, in oral fluid [4, 5] , test performance may be affected by HIV prevalence, stage of illness, use of antiretroviral agents (ARVs), test operator error, and other factors [6] [7] [8] [9] [10] [11] [12] [13] . In HIV prevention trials, preexposure prophylaxis (PrEP) and the potentially high proportion of early infections encountered during intensive sampling may result in failure to detect infection when relying on rapid oral fluid tests. The impact of a false-negative (FN) result is accentuated in this setting, as test recipients might receive PrEP regimens during established infection, or engage in unprotected sex under the false assurance of a negative result when HIV is most likely to be transmitted.
Between 2003 and 2006, the US Centers for Disease Control and Prevention (CDC) undertook 3 cohort studies in MSM and heterosexual persons at risk for acquiring HIV infection in Thailand and Botswana [14] [15] [16] . In these studies, OFOQ was selected for routine monthly HIV testing because of its ease of use, reported high sensitivity and specificity, and rapid turnaround time (Supplementary Figure 1) . To further define the performance of the OFOQ test, we retrospectively examined OFOQ test result accuracy with reference to highly sensitive blood tests in all HIV seroconverting participants in these 3 studies.
METHODS

Ethical Review
The contributing studies were conducted with signed informed consent by participants and approval by the Botswana Health Research and Development Committee, the Ethical Review Committee of the Thai Ministry of Public Health, and the CDC Institutional Review Board.
Contributing Studies and Participant Characteristics
The Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2) was a phase 3, randomized, double-blinded, placebo-controlled clinical trial of oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) PrEP for reducing HIV incidence, performed on 1219 sexually active heterosexual adults in Francistown and Gaborone, Botswana [14] . The Bangkok Tenofovir Study (BTS) was a phase 3, randomized, double-blinded, placebo-controlled clinical trial of daily oral TDF HIV PrEP among 2413 adults who injected drugs in Bangkok, Thailand [15] . The Bangkok MSM Cohort Study (BMCS) investigated the epidemiology of HIV and prevention methods among 1377 Thai MSM in Bangkok [16] . HIV subtype was determined by consensus sequencing in pol (TDF2), or as described elsewhere [15, 17] . In the TDF2 study, all infections were due to HIV type 1 (HIV-1) subtype C, and subtype comparisons were not possible. In BTS and BMCS, infections were due to CRF01-AE, HIV-1 subtype B, and interstrain recombinants, and participants were categorized as infected with HIV-1 subtype B or a non-subtype B strain. PrEP was not given in BMCS. However, 5 BMCS seroconverters received antiretroviral therapy (ART) immediately after diagnosis [18] .
OraQuick Testing
In all contributing studies, all test operators were trained in the use of the OFOQ test by a proficient laboratory staff member. Test operator competency was assessed at intervals using blinded model proficiency evaluation program and College of American Pathologists (CAP) proficiency panels containing known positive and negative samples (TDF2), a panel of blinded negative and positive samples provided by the Thai National Institute of Health (BTS), or CAP proficiency panels containing known positive and negative samples (BMCS). Because test strip interpretation relies on subjective interpretation of chromatographic bands, measures were taken to assure that testing was performed under lighting conditions assessed to be adequate prior to study initiation.
Laboratory Methods
We performed a look-back analysis on stored blood samples in all HIV-infected participants. For each seroconverting individual, samples collected and stored at -70°C at the time of, and prior to, the first reactive OFOQ test were tested in reverse chronological order until the first negative blood sample was obtained. 
Statistical Analysis
Nonreactive OFOQ tests were categorized with reference to a gold standard of EIA and/or NAAT results, or considered unconfirmed if no additional confirmatory testing was available. The primary outcome variable was the proportion of FN results among all negative OFOQ responses in newly infected individuals after the estimated time of infection. The relationships between primary outcomes and potential predictors (eg, participant age, sex, time to test kit expiration, test operator, operator workload, clinic site, ARV exposure, and HIV subtype) were summarized using prevalence ratios (PRs) and robust 95% confidence intervals (CIs) using generalized estimating equations [19] [20] [21] [22] . In secondary analyses we considered (1) what proportion of negative OFOQ tests were obtained after the appearance of HIV-specific (or gp41-specific) antibodies in blood; (2) whether there were any significant differences in ARV exposure (treatment arm assignment), HIV pVL, and subtype distribution between participants with prolonged (ie, >180 days) and those without a prolonged history of FN results, and; (3) whether there were any interactions between participant, test center, test operator, and test kit lot in those with exceptionally frequent FN results (See Supplementary Materials).
RESULTS
Seroconverting Individuals
The TDF2, BTS, and BMCS studies provided 34, 53, and 200 newly infected individuals to this analysis, respectively (N = 287). In this group, geometric mean pVL at the time closest to seroconversion (median, 66.5 days [range, 14.5-934.5 days]) was 47 546 copies/mL (95% CI, 35 553-63 584 copies/ mL). Twenty-four of 87 seroconverting individuals in TDF2 and BTS received PrEP consisting of either TDF or TDF-FTC. Five seroconverting individuals from the BMCS received combination ART immediately after recognition of infection.
FN Tests Across all Studies
Using the midpoint estimate, 233 FN results occurred in 80 seroconverting individuals (Supplementary Table 1 Table 1 ). The median estimated OFOQ seroconversion delay time ( Figure 1 ) was 82 days (range, 20-307.5 days). FN results were significantly associated with test location (PR, 24.4 [95% CI, 4.1-145.3], P < .01), lack of operator proficiency (PR, 3.9 [95% CI, 1.6-9.6], P < .01), operator age <35 years (PR, 3.6 [95% CI, 1.3-9.9], P < .01), and use of test kits ≥100 days prior to kit expiration date (PR, 3.5 [95% CI, 1.7-7.2], P < .01). Participant age, sex, treatment arm, and operator workload were not significant factors ( 
FN OFOQ Results Relative to Appearance of HIV-Specific Antibodies in Blood
Among 233 FN tests, 208 occurred after or on the same day as a positive EIA, while 11 FN confirmed by NAAT came before the last negative EIA and 14 came between last negative and first positive EIAs. Western blot data were available for 122 BTS participants; of these, 97 had a FN result (80%) after the appearance of a gp41 band, and 116 (95%) after the appearance of either a gp41 or a gp160 band.
Prolonged OFOQ False-Negativity and Randomization to PrEP, HIV pVL, and Subtype Distribution
Randomization to PrEP was positively associated with FN OFOQ tests only in the BTS (P = .01). The pVL was significantly lower among participants with OFOQ conversion delay times >180 days in BTS (2557 vs 50 555 copies/mL, P = .016), but not in the BMCS or TDF2 studies (Table 1) . However, there was no significant association between OFOQ delay time >180 days and either ARV exposure or infecting HIV subtype in any study.
Clinic and Operator
We considered the relationship between clinics with higher-than-average FN results and the distribution of FN results among operators at these clinics. BMCS data were not included here because all tests were performed at a single clinic. 
DISCUSSION
We have examined the performance of HIV rapid testing in oral fluid in the context of 2 randomized placebo-controlled PrEP studies and 1 cohort study, involving study participants exposed to HIV through heterosexual contact, homosexual contact, and injection drug use. Eighty of 287 HIV-infected participants had 1 or more FN OFOQ results. Factors significantly associated with FN results in 1 or more studies included test operator, operator proficiency, test location, use of test kits 100 days or more prior to kit expiration date, and randomization to PrEP, while low pVL was associated with prolonged OFOQ conversion delay in 1 study. Operator age was a significant factor in TDF2 and BMCS, but had opposite effects in these 2 studies. Participant age and sex, operator workload, and HIV subtype were not associated with FN results (Table 1) . Most FN results occurred after the appearance of HIV-specific antibody responses in blood. The OFOQ package insert reports a test sensitivity of 99.6% [4] . Most studies cite OFOQ sensitivity values ranging from 97.8% to 100% [9, 11, 12, 23, 24] , although a number of studies have reported lower sensitivity in some settings. Stekler et al noted an OFOQ sensitivity of 80% among 2479 high-risk men and transgender women in Seattle [7] , and Pilcher et al observed a sensitivity of 86.6% among 127 participants in San Francisco [10] . In these 2 studies, failure to detect very early infection and a relative insensitivity of testing in oral fluid compared with equivalent testing in blood were important factors underlying FN OFOQ results. These findings are consistent with studies showing lower antibody titers and/or delayed appearance of antibodies in oral fluid in comparison with blood, and reduced sensitivity of oral fluid-based HIV tests compared with rapid tests in blood [25] [26] [27] [28] . Because we examined incident HIV infections, early infection was a prevailing factor for at least some of the FN results obtained in each individual. However one striking observation in our report is the very prolonged OFOQ conversion delay time occurring in some individuals. In addition, a larger number of study participants had more modest delays exceeding 3 months, and factors other than testing during acute infection must be responsible for detection failures in these cases. One possible contributing factor is exposure to ART. Pavie et al noted an OFOQ sensitivity of only 86.5% among 200 study participants with HIV infection confirmed by Western blot [6] . Most were receiving ART (68.5%) and had plasma HIV-1 RNA <200 copies/mL (57.8%). Other studies also show that FN results are more likely during late-stage infection or during long-term suppressive therapy, where HIV-specific antibody titers may wane [8, 29] . These results are consistent with the significant association between FN results and randomization to PrEP, and the association between prolonged FN status and low pVL observed in the BTS.
In our analysis, certain operators seemed to be more likely than others to obtain a FN result. The OFOQ test requires subjective visual interpretation of chromatographic bands, which may be faint, and this may be challenging under some circumstances. These findings agree with other studies demonstrating the potential for operator error in the use of the OFOQ test [30, 31] . The direct association between time to kit expiration and likelihood of an FN OFOQ result was unexpected and counterintuitive, as it implies better test performance closer to the time of kit expiration. To our knowledge, this is the first report of decreased likelihood of a false-negative OFOQ result as time of testing approaches the kit expiration date. However, Facente et al reported a striking trend toward greater likelihood of a false-positive test result the closer the test was performed to the kit expiration date [32] . These 2 observations remain unexplained, but suggest that a positive test is more likely at times closer to kit expiration, possibly due to unrecognized test properties.
This analysis has several limitations. Because oral fluid and confirmatory testing was performed at intervals, the HIV infection dates were estimated based on testing dates. In participants with periods of loss to follow-up, the methods used to estimate time of infection may underestimate the true OFOQ delay time. Blood sampling was infrequent in the BMCS, resulting in a substantial uncertainty in the estimated OraQuick conversion delay time. In addition, routine EIA testing was implemented in the BMCS after February 2010. Although OraQuick tests were also performed at study visits, reactive EIA results prompted evaluation for HIV infection and obviated further OFOQ testing, thus placing an upper limit on the possible OraQuick delay time.
Plasma viral load was measured infrequently in all studies, possibly obscuring the relationship between pVL and FN results. The OraQuick test requires subjective visual interpretation, and photographic records of test results were not routinely kept. It is therefore difficult to distinguish between the failure of operators to recognize faint bands and true test kit failure.
In this analysis, failure of the OFOQ to detect HIV infection was multifactorial in origin ( Figure 2) . The OFOQ test is accepted as a sensitive and specific test for the diagnosis of HIV infection in a variety of clinical settings, and has been approved for home use by nontechnical users. However, caution must be exercised when interpreting a negative OFOQ test in settings where acute infection is likely, and where PrEP use, ARTinduced viral suppression, or profound immunosuppression may result in low HIV-specific antibody titers. In the setting of clinical trials, investigators should consider diagnostic algorithms relying on multiple tests for detection of infection.
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